Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical trial with the CAR T-cell therapy both as a monotherapy and in combination with OncoSec's TAVO (IL-12) in patients with triple-negative breast cancer

Next Previous
Trial Profile

A clinical trial with the CAR T-cell therapy both as a monotherapy and in combination with OncoSec's TAVO (IL-12) in patients with triple-negative breast cancer

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 05 Jul 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CAR T cell therapy OncoSec Medical/Dana-Farber Cancer Institute (Primary) ; Tavokinogene telseplasmid (Primary)
  • Indications Triple negative breast cancer
  • Focus Adverse reactions
  • Sponsors OncoSec Medical

Most Recent Events

  • 05 Jul 2019 New trial record
  • 27 Jun 2019 According to an OncoSec Medical Incorporated media release, the company plans to conduct the initial clinical trials within the Harvard University network of hospitals.
  • 27 Jun 2019 According to an OncoSec Medical Incorporated media release, the company plans to begin clinical trials with the TNBC CAR T-cell therapy in 2020, both as a monotherapy and in combination with OncoSec's TAVO (IL-12).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top